Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

  • Stifel analyst Dara Azar initiated coverage on Inhibrx Biosciences Inc (NASDAQ:INBX) with a Buy rating and announced a price target of $150. Inhibrx Biosciences shares closed at $62.35 on Tuesday. See how other analysts view this stock.
  • Needham analyst Ami Fadia initiated coverage on MapLight Therapeutics Inc (NASDAQ:MPLT) with a Buy rating and announced a price target of $37. MapLight Therapeutics shares closed at $24.14 on Tuesday. See how other analysts view this stock.
  • Stifel analyst Dara Azar initiated coverage on Summit Therapeutics Inc (NASDAQ:SMMT) with a Buy rating and announced a price target of $45. Summit Therapeutics shares closed at $19.22 on Tuesday. See how other analysts view this stock.
  • Evercore ISI Group analyst Elizabeth Anderson initiated coverage on Elevance Health Inc (NYSE:ELV) with an In-Line rating and announced a price target of $345. Elevance Health shares closed at $311.83 on Tuesday. See how other analysts view this stock.

Considering buying INBX stock? Here’s what analysts think:

Photo via Shutterstock